Mother hugging her smiling daughter with trees in backgroundMother hugging her smiling daughter with trees in backgroundblue triangle graphic

Great Science
Deep Compassion
Real Impact

Working together to address addiction,
serious mental illness and cancer.

Discover Alkermes

Featured News

Woman with bun

October 20, 2021

Alkermes to Report Third Quarter 2021 Financial Results on Oct. 27, 2021

Read more

Man holding blue pills

October 18, 2021

Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder

Read more

September 22, 2021

New Survey Provides Insights Into Drinking Behaviors During the Pandemic

Read more

See all press releases

Smiling woman standing in hallway at Alkermes office.


We champion an approach that views patients holistically and with compassion. Working together with stakeholders across the healthcare community, our team is focused on cutting-edge science, developing innovative medicines and patient-focused advocacy to make a real-world impact in the lives of people living with difficult-to-treat conditions.

Visit our Responsibility page

Driven by Passion

Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.

Learn more about our culture

Man standing in lab coat with mask on in laboratory area at Alkermes.

Man sitting in front of green background at Alkermes office.

COVID-19 Response

In response to urgent and unexpected needs created by the COVID-19 pandemic, Alkermes acted quickly to prioritize the safety of our employees and our communities, and adapted our business practices to support uninterrupted supply of, and patient and provider access to, our medicines and development products.

Read our response

Pipeline Preview

We seek to develop treatments that address unmet patient needs in complex and difficult-to-treat diseases in the areas of neuroscience and oncology. Our pipeline is comprised of clinical and preclinical candidates generated from our scientific platforms, including synaptic dysfunction in neuroscience and immune modulation in oncology.

View our pipeline

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • FDA-Approved
  • Neuroscience

    • LYBALVI® (olanzapine and samidorphan) - Schizophrenia/Bipolar I Disorder

    • ALKS 1140 - Neurology (Orphan)

  • Oncology

    • Nemvaleukin alfa*

*Formerly referred to as ALKS 4230


  We dare for progress every day. 
We take pride in our unique and compassionate spirit.
Our shared mission to make a real impact for others drives our purpose.
With collaboration at our core, we believe that anything is possible.

Working at Alkermes

Man with mask sitting in meeting talking to colleague at Alkermes.

We are driven by some of the most pressing health issues of our time to help advance innovation in hopes of providing additional treatment options for people living with complex and often difficult-to-treat diseases.